MedTrace Logo

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-04-05

No results posted yet for this study

Summary

This randomized pilot clinical trial studies quantitative susceptibility mapping (QSM) and regional dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) permeability using golden-angle cartesian randomized time-resolved (GOCART) technique in evaluating regional gadolinium retention in the brain in patients with intracranial neoplasm receiving gadobenate dimeglumine or gadoterate meglumine. MRI diagnostic techniques such as, QSM and DCE MRI, may help to gather information regarding brain changes associated with gadolinium deposits during 8 to 18 months after administration of gadobenate dimeglumine or gadoterate meglumine.

Conditions

  • Intracranial Neoplasm

Interventions

DEVICE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo GOCART DCE MRI

DRUG

Gadobenate Dimeglumine

Given IV

DRUG

Gadoterate Meglumine

Given IV

DEVICE

Magnetic Resonance Imaging

Undergo QSM and T1WI imaging

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Alexander Lerner · University of Southern California

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2020-04-04
Completion
2021-04-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03091803 on ClinicalTrials.gov